Skip to main content

PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI d

Social Author Name
Dr. John Cush
Tweet Content
PREVENT study looked at Xray progression in 438 nr-axSpA pts given PBO or secukinumab. At baseline there was little SI damage & at 2 yrs no SI progression (− 0.04 mSASSS) or spinal inflammation in both groups. https://t.co/3EgnK2rWgb https://t.co/z5umUhpViF
Show on Archive Page
On
Display in Search Results
On
PDQ
Off